The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma
- Author:
Yumin CHUNG
1
;
Young Chan WI
;
Yeseul KIM
;
Seong Sik BANG
;
Jung Ho YANG
;
Kiseok JANG
;
Kyueng Whan MIN
;
Seung Sam PAIK
Author Information
- Publication Type:Original Article
- Keywords: Smad4; PTEN; Prognosis; Colon neoplasms; Humans
- MeSH: Adenocarcinoma; Adenoma; Cell Proliferation; Colonic Neoplasms; DNA Mismatch Repair; Humans; Prognosis
- From:Journal of Pathology and Translational Medicine 2018;52(1):37-44
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Smad4 and PTEN are prognostic indicators for various tumor types. Smad4 regulates tumor suppression, whereas PTEN inhibits cell proliferation. We analyzed and compared the performance of Smad4 and PTEN for predicting the prognosis of patients with colorectal adenocarcinoma. METHODS: Combined expression patterns based on Smad4+/– and PTEN+/– status were evaluated by immunostaining using a tissue microarray of colorectal adenocarcinoma. The relationships between the protein expression and clinicopathological variables were analyzed. RESULTS: Smad4–/PTEN– status was most frequently observed in metastatic adenocarcinoma, followed by primary adenocarcinoma and tubular adenoma (p<.001). When Smad4–/PTEN– and Smad4+/PTEN+ groups were compared, Smad4–/PTEN– status was associated with high N stage (p=.018) and defective mismatch repair proteins (p=.006). Significant differences in diseasefree survival and overall survival were observed among the three groups (Smad4+/PTEN+, Smad4–/PTEN+ or Smad4+/PTEN–, and Smad4–/PTEN–) (all p<.05). CONCLUSIONS: Concurrent loss of Smad4 and PTEN may lead to more aggressive disease and poor prognosis in patients with colorectal adenocarcinoma compared to the loss of Smad4 or PTEN alone.
